References
- Druker BJ, Tamura S, Buchdunger E, et al Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.
- Pytel D, Sliwinski T, Poplawski T, et al Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009;9:66–76.
- Petrelli A, Valabrega G. Multitarget drugs: the present and the future of cancer therapy. Expert Opin Pharmacother 2009;10:589–600.
- Matin S, Tallman D, Gilliland G, Rowe JM. Drug therapy for acute myeloid leukemia. Drug therapy for acute myeloid leukemia. Blood 2005;14:942–953.
- Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 2007;14:942–953.
- Strumberg D. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. J Clin Oncol 2008;26:3469–3471.
- Crump M, Hedley D, Kamel-Reid S, et al A randomized phase I clinical biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study. Leuk Lymphoma 2010;51:252–260.
- Metzelder S, Wang Y, Wollmer E, et al Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567–6571.
- Zhang W, Konopleva M, Shi YX, et al Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100:184–198.
- Zarrinkar PP, Gunawardane RN, Cramer MD, et al AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia. Blood 2009;1143:2984–2992.